The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)
Status:
Recruiting
Trial end date:
2022-01-08
Target enrollment:
Participant gender:
Summary
Designed as a multi-center, randomized, double-blind, placebo-controlled study to assess the
efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults
with polymerase chain reaction (PCR)-Confirmed COVID-19.